Titleist Asset Management LLC Sells 18,528 Shares of Moderna, Inc. (NASDAQ:MRNA)

Titleist Asset Management LLC cut its holdings in Moderna, Inc. (NASDAQ:MRNA) by 37.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 31,522 shares of the company’s stock after selling 18,528 shares during the quarter. Titleist Asset Management LLC’s holdings in Moderna were worth $1,311,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. Wilmington Savings Fund Society FSB grew its stake in shares of Moderna by 295.0% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock worth $33,000 after purchasing an additional 587 shares during the period. Compass Planning Associates Inc acquired a new position in shares of Moderna during the 4th quarter worth about $37,000. Venturi Wealth Management LLC increased its stake in shares of Moderna by 286.2% in the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock valued at $37,000 after acquiring an additional 664 shares during the last quarter. Crowley Wealth Management Inc. bought a new stake in shares of Moderna in the 4th quarter valued at about $41,000. Finally, MassMutual Private Wealth & Trust FSB raised its position in shares of Moderna by 58.2% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock valued at $44,000 after acquiring an additional 389 shares during the period. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Price Performance

Shares of NASDAQ:MRNA opened at $25.11 on Friday. The company has a market capitalization of $9.71 billion, a P/E ratio of -2.71 and a beta of 2.23. The business’s 50 day simple moving average is $33.55 and its 200 day simple moving average is $42.80. Moderna, Inc. has a 1 year low of $23.76 and a 1 year high of $170.47.

Analysts Set New Price Targets

Several equities research analysts have weighed in on MRNA shares. JPMorgan Chase & Co. cut their target price on shares of Moderna from $40.00 to $33.00 and set an “underweight” rating on the stock in a report on Friday, March 21st. Leerink Partners reduced their target price on Moderna from $31.00 to $27.00 and set an “underweight” rating on the stock in a report on Thursday, January 16th. Bank of America dropped their price target on Moderna from $41.00 to $34.00 and set an “underperform” rating on the stock in a research report on Tuesday, February 11th. Barclays lowered Moderna from an “overweight” rating to an “equal weight” rating and decreased their price objective for the company from $111.00 to $45.00 in a research report on Tuesday, February 18th. Finally, Berenberg Bank raised their target price on shares of Moderna from $33.00 to $42.00 and gave the stock a “hold” rating in a report on Thursday, January 16th. Four equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $59.00.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.